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Abstract The ability of cells to organize collagen fibrils is 
fundamental to a variety of processes found in embryogenesis, 
wound healing, fibrosis, and scar formation. We previously 
isolated a monoclonal antibody (mAb A3A5) which inhibits 
human fibroblast-mediated collagen gel contraction, an in vitro 
model producing the process of collagen morphogenesis. Human 
fibronectin (FN) has been shown to be the antigen of A3A5. The 
present study aimed at identifying the A3A5 epitope to reveal the 
mode of binding between collagen, FN, and fibroblasts in the 
process of gel contraction. The epitope was sought in FN 
fragments obtained by pepsin digestion and in recombinant FN 
fragments expressed in Escherichia coli by determining their 
immunological reactivity with A3A5, and was identified as a 
short segment consisting of the fourth through the amino half of 
the fifth FN type III. We propose a new functional domain of FN 
which plays a crucial role in the binding of fibroblasts to collagen 
fibrils and is involved in collagen morphogenesis. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Fibroblasts populated in 3-dimensional lattices of collagen 
bind collagen fibrils and organize them into more dense and 
compact structures [1-4]. This cellular process is thought to be 
an in vitro model of the collagen morphogenesis found in a 
wide variety of biological processes such as embryogenesis, 
organogenesis, and wound healing [5,6]. However, the mech-
anism of cell-mediated gel contraction has been largely un-
known. 
Binding between fibroblasts and collagen fibrils is evidently 
the first and key step of the consecutive events taking place in 
gel contraction. Among such binding processes, the direct 
interaction of cell surface integrins with collagens appears to 
be important [7]. In fact, a recent work showed that the bind-
ing of a2Pi-integrin receptors to type I collagen is involved in 
the contraction of hydrated collagen lattices [8]. Indirect in-
teractions of cells with collagen mediated by fibronectin (FN) 
might also be crucial for gel contraction because FN possesses 
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the ability to bind both collagen and cell surface [7]. However, 
the role of FN in collagen gel contraction has been contro-
versial. Some studies showed that the FN-mediated reaction is 
not involved in gel contraction [9,10], while other studies sug-
gested the involvement of FN in the process and proposed 
that FN links cell surface molecules to the surrounding colla-
gen fibrils [11-13]. 
Previously, we obtained a monoclonal antibody (mAb) 
called A3A5 that blocks the initial phase of human fibro-
blasts-mediated collagen gel contraction [13]. This mAb was 
found to be reactive with both plasma (pFN) and cellular FN 
(cFN) in human, indicating the involvement of FN in collagen 
gel contraction. Therefore, determination of the epitope of 
this unique mAb appeared to be useful and important to 
gain an insight into the mechanism of gel contraction. Espe-
cially, epitope identification is pivotal to know which domain 
of an FN molecule is responsible for mediating the binding 
between collagen and fibroblasts. 
FN is a high-molecular-mass heterodimeric glycoprotein 
consisting of three types of modules (type I, type II, and 
type III repeat) and plays an important role in diverse phe-
nomena including cell attachment, cell spreading, cell migra-
tion, wound healing, and tumor metastasis (for reviews, see 
[7,14]). The present study located the A3A5 epitope on a 
human FN molecule. Identification of A3A5-reactive frag-
ments in the pepsin digests of FN revealed that the epitope 
is included in the region ranging from III4 to IIIQ modules. 
This epitope region was further shortened to a 122-amino-acid 
sequence in the III4 repeat through the amino half of III5 
repeat by testing the A3A5 reactivity of polymerase chain 
reaction (PCR)-generated FN fragments. These results suggest 
that this specific short segment of FN has a biologically sig-
nificant role in complex interactions between cells and colla-
gen fibrils taking place on the cell surface which lead to col-
lagen morphogenesis. 
2. Material and methods 
2.1. Materials 
Materials and chemicals were obtained as follow: human pFN from 
BioMedical Technology, Inc. (Boston, MA); immobilized pepsin from 
Pierce (Rockford, IL); ECL detection kits from Amersham Japan 
(Tokyo); peroxidase conjugated with second antibody from Dainihon 
Pharmaceutical Co. Ltd. (Tokyo); BaBl exonuclease, and malE gene 
fusion vector pMAL-c2 and restriction endonucleases of Xmrii., Sail, 
BamHl, and Pstl from New England Biolabs (Beverly, MA); Taq 
polymerase from Perkin Elmer (Norwalk, CT); Escherichia coli (E. 
coli) cells (JM109) from Toyobo (Tokyo); NuSieve GTG low-melting 
agarose and (3-agarose from FMC BioProducts (Rockland, ME); 
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pCRII vectors from Invitrogen (San Diego, CA); Immobilon poly-
vinylidene difluoride (PVDF) transfer membranes from 
Millipore (Bedford, MA); CHROMA SPIN-200 columns from 
Clontech (Palo Alto, CA). Reagents not specified otherwise were 
of analytical grade and purchased from Wako Pure Chemicals Inc. 
(Tokyo). 
2.2. Western immunoblot analysis of FN fragments 
Human pFN (2 mg/ml) was digested with immobilized pepsin in 
0.15 M NaCl and 25 mM glycine buffer (pH 2.0) at 37°C for 2 h at a 
protease/substrate ratio of 1:4. The enzyme was then removed by 
centrifugation, and the supernatants which contained fibronection 
fragments were recovered. The fragments were precipitated with 5% 
trichloroacetic acid and solubilized in electrophoresis sample buffer 
containing 2% sodium dodecyl sulfate (SDS) and 0.1 M dithiothreitol. 
After neutralized with 0.1 N NaOH, peptides in the solution were 
electrophoresed in wide slots (30 mm) of 9X 10 cm 4-20% gradient 
polyacrylamide-SDS gels (SDS-PAGE) and transferred to Immobilon 
PVDF membranes. The PVDF blots were washed with the solution of 
0.15 M NaCl, 50 mM Tris-HCl (pH 7.6), and 0.05% Tween-20 
(TBST), dipped in 1% bovine serum albumin in TBST for 30 min, 
and then reacted for 1 h with the hybridoma culture supernatants of 
A3A5 mAb [13]. The blots were extensively washed with TBST, in-
cubated for 1 h in TBST containing horseradish peroxidase-conju-
gated second antibodies, and washed extensively with TBST. A3A5-
reactive fragments were visualized by a ECL kit according to the 
manufacture's instruction. 
visualization of antigen with antibodies was performed by color de-
tection using 3,3'-diaminobenzidine (DAB) [17]. 
2.5. Preparation of deletion mutants of clone PCR(X)-18 by 
site-directed PCR mutagenesis 
The clone PCR(X)-18 was deleted from its 5'- or 3'-terminus by 
site-directed PCR mutagenesis and four deletion mutants were ob-
tained: clone 3/6 cover a region from nucleotide 2633 to 3175 of 
the GenBank sequence HUMFNMC, clone 3/25 from 2633 to 3110, 
clone 3/24 from 2633 to 2998, and clone 9/7 from 3176 to 3438. 
Primers utilized are described for each clone in the sequence of 5' 
sense primer and 3' antisense primer, respectively: Fn3N (see Section 
2.4 describing the construction of cDNAs for FN segments) and 
Fn6C (CCGGATCCGGTAAAGACTCCAGTGGCTT, BamHl site 
underlined, 28-mer) for clone 3/6; Fn3N and Fn25C (CCGGATC-
CAGGCTGCAGATTCCTCAGGG, 28-mer) for clone 3/25; Fn3N 
and Fn24C (CCGGATCCTATCTGGGCCCGAGGTGGAG, 28-
mer) for clone 3/24; and Fn9N (CCGGATCCGGGAGCTCTATTC-
CACCTTA, 28-mer) and Fn7C (CCGGATCCCACCACTTTGTT-
TACAATTG, 28-mer) for clone 9/7. 
2.3. Amino acid sequencing 
FN was digested with pepsin, separated on gels as described above, 
and visualized with Coomassie blue. Peptide bands were cut out with 
a scalpel and sequenced by a gas-phased protein sequencer of Applied 
Biosystems (Foster City, CA). 
2.4. Construction of cDNAs for FN segments 
A cDNA clone (pFHIOO) coding for the full length of FN except 
ED domains was generously provided by Dr. A. Kornblihtt (INGE-
BI-CONICET, Argentina). All nucleotide sequences are numbered 
according to GenBank file HUMFNMC of Kornblihtt [15]. Two dif-
ferent cDNA segments covering A3A5-reactive fragments of FN were 
constructed as follow: pFHIOO cDNA was linearized by digesting 
with restriction enzyme Sail (at 1592 bp) and then digested with 
BaBl exonuclease. The resulting cDNA fragments were further di-
gested with either Pstl (at 2657 bp) or BamHI (at 4086 bp). These 
DNA fragments were inserted into pMAL-c2 plasmid vectors coding 
for maltose-binding protein (MBP) which had been treated with either 
Xmnl and Pstl, or Xmnl and BamHl. The correct coding frame of 
pMAL-c2 recombinant clones was verified by nucleotide sequencing 
of the insert DNA. The unidirectional expression of the recombinants 
was carried out as described by Maina et al. [16]. 
The fourth to sixth type III repeats of FN which include the two 
A3A5-positive fragments (P2 and P3) were amplified by the polymer-
ase chain reaction (PCR) using pFHIOO DNA as template and two 
different BamHl site-franked primers: 5' sense primer, Fn3N 
(CCGGATCCGTGCCCTCTCCCAGGGACCT, BamHl site under-
lined, 28-mer), and 3' antisense primer, Fn7C (CCGGATCCCAC-
CACTTTGTTTACAATTG). These oligonucleotides were synthesized 
by an Applied Biosystems 391 DNA synthesizer. The PCR reaction 
was carried out in 25 itl of the solution consisting of 20 mM Tris-HCl 
(pH 8.4), 50 mM KC1, 1 mM dNTP mix (dATP, dGTP, dCTP, and 
dTTP), 2.5 ng pFH 100, 1 pmol of each of primers, and 1 U of Taq 
polymerase. 
Amplification was performed for 25 cycles of a consecutive incuba-
tion at 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s, and finally at 
72 for 10 min. The PCR product (805 bp in length) was first sub-
cloned into the pCRII vector following the manufacture's protocol. 
The insert DNA was removed from the vector by digesting with 
BamHl, then electrophoretically purified on a low-melting agarose 
gel. A gel band containing the insert was excised and digested with 
P-agarose to release the insert DNA. The DNA was further purified 
by passing through a CHROMA SPIN-200 column, then subcloned 
into BamHI site of pMAL-c2 plasmid for E. coli expression. This 
clone was named as PCR(X)-18. 
The proteins fused with MBP were prepared as recommended by 
the manufacturer and were analyzed by 4-20% gradient SDS-PAGE, 
or Western immunoblot analysis as described above, except that the 
Fig. 1. Reactivity of fragments of human pFN to the mAb A3A5. 
FN was digested with pepsin, electorphoretically separated, and sub-
jected to the Western blotting. Left: Coomassie blue staining. 
Right: Western immunoblot analysis by the ECL film detection sys-
tem. Molecular weights were determined by the migration of stand-
ard proteins and are shown in kDa at the left side. Five bands de-
tected on the Coomassie blue-stained gel or the immunoblots were 
designated as PI through P5 and subjected to amino acid sequenc-
ing. 
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3. Results 
3.1. Confinement of the epitope ofmAb A3A5 in a region 
spanning Ilh to IIIQ 
Human pFN was partially cleaved by pepsin, separated on 
a SDS-PAGE gel, and was subjected to the Western blotting 
with mAb A3A5 (Fig. 1). Five fragments (P1-P5) were se-
lected for amino acid sequencing as shown in Fig. 1. P2 and 
P3, but not P4, were found to be immunologically reactive 
with mAb A3A5. P2, P3, and P4 gave their amino terminal 
sequences as follows: P2, ETTCTRSDTV (E at amino acid 
870 or nucleotide 2609); P3, SVTEITASS (S at 700 or 2099); 
and P4, VTTIPAPTDLKPTQVT (V at 1602 or 4805). Their 
carboxyl end was estimated from their molecular weights (65 
kDa for P2, 50 kDa for P3, and 30 kDa for P4). Positive 
fragments of P2 and P3 shared the region spanning III4—III6 
domain, while a negative fragment of P4 located in a region 
containing IIIn III14 (Fig. 2A) which is a carboxyl terminal 
side of the cell-binding sequence (RGD) in III10. Thus, it is 
clear that the immunological recognition of mAb A3A5 is 
sequence-specific and its epitope locates within the III4—III6 
region. 
To confirm this conclusion on the epitope location, FN 
cDNA segments coding for III4—III6 repeats were expressed 
as proteins fused with MBP in E. coli and their reactivity to 
the mAb was tested by Western immunoblotting. As sche-
matically shown in Fig. 2A, three clones were prepared by 
deleting appropriate region of pFHIOO clones: clone #18 cov-
ered a region from Val587 (or nucleotide bp 1760) to Leu886 
(2657); clone #160 from Glu857 (2570) to He1363 (4088); clone 
PCR(x)-18 from Asp878 (2633) to Leu1058 (3173). Thus, clone 
#18 included IIIi through III3, clone #160 III3 through most 
III9, and clone PCR(X)-18 III4 through III6. The fusion pro-
teins with expected sizes were efficiently expressed as shown in 
Fig. 2Bc in which gels were stained with anti-MBP antibodies. 
A number of polypeptides whose molecular weights were low-
er than expected ones were also detected by antibody binding. 
These might be degradation products due to endogenous pro-
teases present in E. coli. Western immunoblotting using mA-
b A3A5 is shown in Fig. 2Bb, which clearly demonstrates that 
the mAb recognizes products of both #160 and PCR(X)-18 
clones, but not that of clone #18. As expected, mAb A3A5 
bound to plasma FN but not MBP. These results indicate that 
reactivity of the mAb is FN-segment specific, and confirm the 
Fig. 2. The A3A5 epitope is located in the 4th to 6th type III repeat of human FN. A: Schematic representation of locations of peptides tested 
on human FN. A central part of a subunit of a dimeric FN molecule is presented. Three vertical lines above the FN molecule represent the lo-
cation of three pepsin digests, the upper, middle, and lower line being P4, P2 and P3, respectively, and those below the molecule represent the 
location of peptides encoded by clone #18, #160, and PCR(X)-18, respectively. Clones #18, #160, and PCR(X)-18 code for FN sequences of 
bp 1760-2657 (amino acid 587-886), bp 2570-4088 (amino acid 857-1363), and bp 2633-3173 (amino acid 878-1058), respectively. These se-
quences were defined according to the GenBank sequence HUMFNMC. B: A3A5 reactivity of products encoded by recombinant cDNAs of 
FN fragments. The FN segments were expressed in E. coli as MBP fusion proteins. E. coli lysates were separated on a 4-20% gradient gel of 
SDS-PAGE and were stained with Coomassie blue (a), or processed for immunoblot analysis probed with either mAb A3A5 (b) or polyclonal 
anti-MBP antibodies (c). Lane 1: E. coli lysates containing vectors without the insert; 2, clone #18; 3, clone PCR(X)-18; 4, clone #160; 5, hu-
man pFN (1 (xg). Open triangles marked at the right side of each lane in (a) indicate the polypeptides of MBP (lane 1) and MBP fusion pro-
teins (lanes 2-4) with the expected sizes. The number on the left side represents molecular weights in kDa. Lower molecular mass polypeptides 
detected by the antibody-binding might be degradation products due to E. coli proteases. 
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Fig. 3. Effect of mutations in the epitope region on their reactivity to A3A5. A: Schematic representation of amino- or carboxyl-terminal dele-
tion of the epitope expressed by PCR(X)-18. B: Western blotting of mutants. Immunoblottings in (b) were carried out as in Fig. 2B. Mutants 
were constructed by the site-directed PCR mutagenesis. Proteins were stained by Coomassie blue (a). Open triangles marked at the right side of 
the panel indicate MBP fusion proteins with the expected sizes. Arabic numerals at the left represent molecular weights in kDa. Lanes 1-5: 
E. coli cell lysates of clone 3/24, clone 3/25, clone 9/7, clone 3/6, and clone PCR(X)-18. 
conclusion obtained by the pepsin-digestion experiment that 
the epitope of the mAb is within the III4-III6 domain (amino 
acid 878-1058 or, nucleotide 2633-3173). In addition, it is 
clear that the sugar moieties present in this region [7] are 
not involved in the antigenic determinant for the mAb, since 
bacterial cells lack the machinery for adding carbohydrate 
chains to proteins. 
3.2. Further confinement of the epitope region by recombinant 
PCR mutagenesis 
To shorten the epitope region further, PCR(X)-18 clones 
were deleted from their 5'- or 3'-end by PCR mutagenesis. 
Deletion mutants were cloned into pMAL-c2 vectors and ex-
pressed as MBP fusion proteins in E. coli. The reactivity of 
the expressed proteins to mAb A3A5 was checked by the 
Western immunoblotting (Fig. 3B). The proteins produced 
by mutant clones of 3/6, 3/24, and 3/25 were positive as that 
of the original clone PCR(X)-18, whereas the Illg repeat ex-
pressed by clone 9/7 was negative. Clone 3/24 codes for the 
whole III4 (amino acid 878-968) and the amino-terminal one-
third of III5 (969-999) and was the shortest positive clone we 
could obtain. Further narrowing the epitope region by this 
method was not successful because there were difficulties in 
expressing MBP fusion proteins reactive to mAb A3A5 when 
the size of inserts was smaller than that of clone 3/24 (data not 
shown). It appears that there is a lower limitation of insert 
DNA size to be expressed in E. coli with pMAL-c2 vector. 
Therefore, the minimal epitope region we could identify by 
the methods presently adopted was a region expressed by 
clone 3/24 which codes for a FN segment composed of 122 
amino acid residues (amino acid 878-999 or nucleotide 2633-
2998). 
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4. Discussion 
Previously we succeeded in screening a unique mAb A3A5 
from hybridomas obtained from mouse cells immunized with 
human skin fibroblasts. The mAb recognizes human FN as its 
antigen and inhibits fibroblasts-mediated collagen gel contrac-
tion [13]. A3A5 seems to interrupt an interaction step between 
fibroblasts and collagen fibrils because mAb A3A5 immuno-
logically stains fibroblasts cultured on gelatin but not those on 
collagen fibrils [13]. Therefore, elucidation of an epitope rec-
ognized by the antibody was expected to contribute to the 
understanding of the mode of interactions among fibroblasts, 
FN, and collagen fibrils which take place in 3-dimensional 
architecture. 
The present study was undertaken to determine the A3A5 
epitope in the FN molecule. We first attempted to identify 
A3A5-reactive fragments in pepsin digests of FN. As a result, 
a region of the III4Hie modules was obtained as an over-
lapping sequence between two reactive fragments. The pres-
ence of the epitope within the III4—III6 modules was con-
firmed by producing an A3A5-positive fusion protein in E. 
coli which bears plasmids containing cDNAs coding for the 
module as an insert. This recombinant fusion protein method-
ology further confined the epitope in the region containing 
about 300 amino acid residues. The recombinant PCR muta-
genesis successfully produced A3A5-reactive deletion mutant 
cDNAs and could shortened the epitope region to a sequence 
composed of 122 amino acid residues in the III4-III5 region. 
The actual mechanism of inhibition of collagen gel contrac-
tion by mAb A3A5 is not known at present. It has been 
shown that cFN but not pFN participates in gel contraction 
[18]. Morla and Ruoslahti [19] previously demonstrated an 
important role of the IIIi module of FN in the polymerization 
of FN and/or its assembly with other matrix components 
which take place on the cell surface. The interaction of the 
III! module with amino-terminal regions of FN is necessary 
for FN self-assembly and is a conformation-dependent proc-
ess [20]. The epitope of A3A5 (III4-III5 repeat) is located near 
the IIIi module and, therefore, antibody binding to the epit-
ope may cause a steric change in the region containing IIIi 
and hinder IIIi module-dependent process of FN self-assem-
bly. The hindrance might explain the inhibitory action of 
A3A5 on cell-mediated collagen gel contraction. It is also 
plausible that binding of the mAb to cell surface FN inhibits 
a direct binding of FN to collagen fibrils which is mediated 
through an unknown site of FN as well as a well-character-
ized gelatin-binding domain [7,14]. There also remains the 
possibility that the epitope itself can specifically bind to col-
lagen fibrils. 
We succeeded in demonstrating that the novel domain con-
sisting of the III4-III5 repeat of FN is involved in collagen gel 
contraction. Since this domain is neither located at the inte-
grin-binding domain nor at the classical gelatin-binding do-
main [7,14], the new mode of interaction is strongly suggested 
among FN, cells and collagen fibrils. We are attempting to 
identify a protein(s) which directly interacts with the domain 
of FN. This might be a fragment of collagen molecule or some 
specific cell surface protein. 
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